An innovative, multicenter clinical trial

combining pharmaceutical and lifestyle interventions for dementia prevention

The MET-FINGER trial is an international, randomized clinical trial, based on the ground-breaking work of the FINGER study, with the aim of preventing cognitive decline and dementia.

For the first time, the FINGER prevention model, which focuses on modifiable lifestyle and vascular risk factors, will be tested in association with metformin in older adults with increased risk of dementia. Based over three sites in the UK, Finland, and Sweden, the trial will include a total of 600 participants.

Metformin is an approved drug that is used to treat type 2 diabetes. It may help prevent dementia and cognitive decline by controlling high blood glucose levels, a well-known risk factor for dementia.

Recruitment to the trial started in the UK in early 2023 and began in Finland and Sweden in mid 2023.

If this intervention proves effective, the MET-FINGER trial could set the stage for the development of clinical trials combining lifestyle intervention and medications world-wide.

Main Collaborators

Karolinska University Hospital, Finnish Institute for Health and Welfare, and Imperial College London


Alzheimer´s Drug Discovery Foundation, Part the Cloud – Gates Partnership Grant Program at Alzheimer´s Association, Alzheimerfonden, and the Office of ALF of the Swedish Research Council.